{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T14:08:01Z","timestamp":1791986881218,"version":"4.4.0"},"reference-count":114,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:00:00Z","timestamp":1724889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:00:00Z","timestamp":1724889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Alma Mater Studiorum - Universit\u00e0 di Bologna"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We provide updated guidance and standards for the indication, acquisition, and interpretation of [<jats:sup>18<\/jats:sup>F]FDG PET\/CT for plasma cell disorders. Procedures and characteristics are reported and different scenarios for the clinical use of [<jats:sup>18<\/jats:sup>F]FDG PET\/CT are discussed. This document provides clinicians and technicians with the best available evidence to support the implementation of [<jats:sup>18<\/jats:sup>F]FDG PET\/CT imaging in routine practice and future research. <\/jats:p>","DOI":"10.1007\/s00259-024-06858-9","type":"journal-article","created":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T10:04:33Z","timestamp":1724925873000},"page":"171-192","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["EANM guidelines on the use of [18F]FDG PET\/CT in diagnosis, staging, prognostication, therapy assessment, and restaging of plasma cell disorders"],"prefix":"10.1007","volume":"52","author":[{"given":"Cristina","family":"Nanni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe M.","family":"Deroose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sona","family":"Balogova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantin","family":"Lapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Withofs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manil","family":"Subesinghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastien","family":"Jamet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1422-7305","authenticated-orcid":false,"given":"Elena","family":"Zamagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Ippolito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Delforge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francoise","family":"Kraeber-Bod\u00e9r\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,29]]},"reference":[{"key":"6858_CR1","doi-asserted-by":"publisher","unstructured":"van de Donk, Niels WCJ, Pawlyn C, Yong KL. Multiple myeloma. Lancet (Br Ed). 2021. https:\/\/doi.org\/10.1016\/S0140-6736(21)00135-5.","DOI":"10.1016\/S0140-6736(21)00135-5"},{"key":"6858_CR2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008733","author":"E Zamagni","year":"2022","unstructured":"Zamagni E, Barbato S, Cavo M. How I treat high-risk multiple myeloma. Blood. 2022. https:\/\/doi.org\/10.1182\/blood.2020008733.","journal-title":"Blood"},{"key":"6858_CR3","doi-asserted-by":"publisher","unstructured":"Caers J, Garderet L, Kort\u00fcm KM, O'Dwyer ME, van de Donk, Niels WCJ, Binder M, Dold SM, Gay F, Corre J, Beguin Y, Ludwig H, Larocca A, Driessen C, Dimopoulos MA, Boccadoro M, Gramatzki M, Zweegman S, Einsele H, Cavo M, Goldschmidt H, Sonneveld P, Delforge M, Auner HW, Terpos E, Engelhardt M. European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. Haematologica (Roma). 2018. https:\/\/doi.org\/10.3324\/haematol.2018.189159.","DOI":"10.3324\/haematol.2018.189159"},{"key":"6858_CR4","doi-asserted-by":"publisher","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, Leleu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BGM, San Miguel JF. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. 2014. https:\/\/doi.org\/10.1016\/S1470-2045(14)70442-5.","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"6858_CR5","doi-asserted-by":"publisher","unstructured":"Greipp PR, San Miguel J, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J, Durie BGM, Crowley JJ, Barlogie B, Blade J, Boccadoro M, Child JA, Harousseau J, Kyle RA. International staging system for multiple myeloma. 2005. https:\/\/doi.org\/10.1200\/JCO.2005.04.242.","DOI":"10.1200\/JCO.2005.04.242"},{"key":"6858_CR6","doi-asserted-by":"publisher","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, Bringhen S, Gay F, Attal M, Passera R, Spencer A, Offidani M, Kumar S, Musto P, Lonial S, Petrucci MT, Orlowski RZ, Zamagni E, Morgan G, Dimopoulos MA, Durie BGM, Anderson KC, Sonneveld P, San Miguel J, Cavo M, Rajkumar SV, Moreau P. Revised international staging system for multiple myeloma: a report from international myeloma working group. 2015. https:\/\/doi.org\/10.1200\/JCO.2015.61.2267.","DOI":"10.1200\/JCO.2015.61.2267"},{"key":"6858_CR7","doi-asserted-by":"publisher","unstructured":"D'Agostino M, Cairns DA, Lahuerta JJ, Wester R, Bertsch U, Waage A, Zamagni E, Mateos M, Dall'Olio D, van de Donk NWCJ, Jackson G, Rocchi S, Salwender H, Blad\u00e9 Creixenti J, van der Holt B, Castellani G, Bonello F, Capra A, Mai EK, D\u00fcrig J, Gay F, Zweegman S, Cavo M, Kaiser MF, Goldschmidt H, Hern\u00e1ndez Rivas JM, Larocca A, Cook G, San-Miguel JF, Boccadoro M, Sonneveld P. Second Revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project. 2022. https:\/\/doi.org\/10.1200\/JCO.21.02614.","DOI":"10.1200\/JCO.21.02614"},{"key":"6858_CR8","doi-asserted-by":"publisher","unstructured":"Durie BGM, Harousseau J, Miguel JS, Blad\u00e9 J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV. International uniform response criteria for multiple myeloma. 2006. https:\/\/doi.org\/10.1038\/sj.leu.2404284.","DOI":"10.1038\/sj.leu.2404284"},{"key":"6858_CR9","doi-asserted-by":"publisher","unstructured":"Dimopoulos MA, Moreau P, Terpos E, Mateos M, Zweegman S, Cook G, Delforge M, H\u00e1jek R, Schjesvold F, Cavo M, Goldschmidt H, Facon T, Einsele H, Boccadoro M, San\u2010Miguel J, Sonneveld P, Mey U. Multiple myeloma: EHA\u2010ESMO clinical practice guidelines for diagnosis, treatment and follow\u2010up. 2021. https:\/\/doi.org\/10.1097\/HS9.0000000000000528.","DOI":"10.1097\/HS9.0000000000000528"},{"key":"6858_CR10","doi-asserted-by":"publisher","unstructured":"Ludwig H, Miguel JS, Dimopoulos MA, Palumbo A, Garcia Sanz R, Powles R, Lentzsch S, Ming Chen W, Hou J, Jurczyszyn A, Romeril K, Hajek R, Terpos E, Shimizu K, Joshua D, Hungria V, Rodriguez Morales A, Ben-Yehuda D, Sondergeld P, Zamagni E, Durie B. International Myeloma Working Group recommendations for global myeloma care. 2014. https:\/\/doi.org\/10.1038\/leu.2013.293.","DOI":"10.1038\/leu.2013.293"},{"key":"6858_CR11","doi-asserted-by":"publisher","unstructured":"Terpos E, Zamagni E, Lentzsch S, Drake MT, Garc\u00eda-Sanz R, Abildgaard N, Ntanasis-Stathopoulos I, Schjesvold F, de la Rubia J, Kyriakou C, Hillengass J, Zweegman S, Cavo M, Moreau P, San-Miguel J, Dimopoulos MA, Munshi N, Durie BGM, Raje N. Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. 2021. https:\/\/doi.org\/10.1016\/S1470-2045(20)30559-3.","DOI":"10.1016\/S1470-2045(20)30559-3"},{"key":"6858_CR12","doi-asserted-by":"publisher","unstructured":"Ludwig H, Delforge M, Facon T, Einsele H, Gay F, Moreau P, Avet-Loiseau H, Boccadoro M, Hajek R, Mohty M, Cavo M, Dimopoulos MA, San-Miguel JF, Terpos E, Zweegman S, Garderet L, Mateos M, Cook G, Leleu X, Goldschmidt H, Jackson G, Kaiser M, Weisel K, van de Donk, Niels W C J, Waage A, Beksac M, Mellqvist UH, Engelhardt M, Caers J, Driessen C, Blad\u00e9 J, Sonneveld P. Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. 2018. https:\/\/doi.org\/10.1038\/s41375-018-0040-1.","DOI":"10.1038\/s41375-018-0040-1"},{"key":"6858_CR13","doi-asserted-by":"publisher","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, Verzijlbergen FJ, Barrington SF, Pike LC, Weber WA, Stroobants S, Delbeke D, Donohoe KJ, Holbrook S, Graham MM, Testanera G, Hoekstra OS, Zijlstra J, Visser E, Hoekstra CJ, Pruim J, Willemsen A, Arends B, Kotzerke J, Bockisch A, Beyer T, Chiti A, Krause BJ. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015. https:\/\/doi.org\/10.1007\/s00259-014-2961-x.","DOI":"10.1007\/s00259-014-2961-x"},{"key":"6858_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-017-5023-5","author":"F Stacul","year":"2018","unstructured":"Stacul F, Bertolotto M, Thomsen HS, Pozzato G, Ugolini D, Bellin M, Bongartz G, Clement O, Heinz-Peer G, van der Molen A, Reimer P, Webb JAW. Iodine-based contrast media, multiple myeloma and monoclonal gammopathies: literature review and ESUR Contrast Media Safety Committee guidelines. Eur Radiol. 2018. https:\/\/doi.org\/10.1007\/s00330-017-5023-5.","journal-title":"Eur Radiol"},{"issue":"1","key":"6858_CR15","first-page":"29","volume":"1","author":"R Rakheja","year":"2011","unstructured":"Rakheja R, Ciarallo A, Alabed YZ, Hickeson M. Intravenous administration of diazepam significantly reduces brown fat activity on 18F-FDG PET\/CT. Am J Nucl Med Mol Imaging. 2011;1(1):29\u201335.","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"6858_CR16","doi-asserted-by":"publisher","unstructured":"S\u00f6derlund V, Larsson SA, Jacobsson H. Reduction of FDG uptake in brown adipose tissue in clinical patients by a single dose of propranolol. 2007. https:\/\/doi.org\/10.1007\/s00259-006-0318-9.","DOI":"10.1007\/s00259-006-0318-9"},{"key":"6858_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s11307-009-0207-2","author":"MGG Sturkenboom","year":"2009","unstructured":"Sturkenboom MGG, Hoekstra OS, Postema EJ, Zijlstra JM, Berkhof J, Franssen EJF. A randomised controlled trial assessing the effect of oral diazepam on 18F-FDG uptake in the neck and upper chest region. Mol Imaging Biol. 2009. https:\/\/doi.org\/10.1007\/s11307-009-0207-2.","journal-title":"Mol Imaging Biol"},{"issue":"4","key":"6858_CR18","first-page":"404","volume":"60","author":"O Belohlavek","year":"2016","unstructured":"Belohlavek O, Jaruskova M. [18F]FDG-PET scan in patients with fasting hyperglycemia. Q J Nucl Med Mol Imaging. 2016;60(4):404\u201312.","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"6858_CR19","doi-asserted-by":"publisher","unstructured":"Caobelli F, Pizzocaro C, Paghera B, Guerra UP. Proposal for an optimized protocol for intravenous administration of insulin in diabetic patients undergoing (18)F-FDG PET\/CT. 2013. https:\/\/doi.org\/10.1097\/MNM.0b013e32835d1034.","DOI":"10.1097\/MNM.0b013e32835d1034"},{"key":"6858_CR20","doi-asserted-by":"publisher","unstructured":"Moulopoulos LA, Koutoulidis V, Hillengass J, Zamagni E, Aquerreta JD, Roche CL, Lentzsch S, Moreau P, Cavo M, Miguel JS, Dimopoulos MA, Rajkumar SV, Durie BGM, Terpos E, Delorme S. Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group. 2018. https:\/\/doi.org\/10.1038\/s41408-018-0124-1.","DOI":"10.1038\/s41408-018-0124-1"},{"key":"6858_CR21","doi-asserted-by":"publisher","unstructured":"Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson DR, Plevak ME, Therneau TM, Greipp PR. Review of 1027 patients with newly diagnosed multiple myeloma. 2003. https:\/\/doi.org\/10.4065\/78.1.21.","DOI":"10.4065\/78.1.21"},{"key":"6858_CR22","doi-asserted-by":"publisher","unstructured":"Regelink JC, Minnema MC, Terpos E, Kamphuis MH, Raijmakers PG, Pieters \u2013 van den Bos, Indra C., Heggelman BGF, Nievelstein R, Otten RHJ, Lammeren \u2013 Venema D, Zijlstra JM, Arens AIJ, Rooy JW, Hoekstra OS, Raymakers R, Sonneveld P, Ostelo RW, Zweegman S. Comparison of modern and conventional imaging techniques in establishing multiple myeloma\u2010related bone disease: a systematic review. 2013. https:\/\/doi.org\/10.1111\/bjh.12346.","DOI":"10.1111\/bjh.12346"},{"key":"6858_CR23","doi-asserted-by":"publisher","unstructured":"Hillengass J, Usmani S, Rajkumar SV, Durie BGM, Mateos M, Lonial S, Joao C, Anderson KC, Garc\u00eda-Sanz R, Riva E, Du J, van de Donk N, Berdeja JG, Terpos E, Zamagni E, Kyle RA, San Miguel J, Goldschmidt H, Giralt S, Kumar S, Raje N, Ludwig H, Ocio E, Schots R, Einsele H, Schjesvold F, Chen W, Abildgaard N, Lipe BC, Dytfeld D, Wirk BM, Drake M, Cavo M, Lahuerta JJ, Lentzsch S. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. 2019. https:\/\/doi.org\/10.1016\/S1470-2045(19)30309-2.","DOI":"10.1016\/S1470-2045(19)30309-2"},{"key":"6858_CR24","doi-asserted-by":"publisher","unstructured":"Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, Hajek R, Dimopoulos MA, Ludwig H, Einsele H, Zweegman S, Facon T, Cavo M, Terpos E, Goldschmidt H, Attal M, Buske C. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2017. https:\/\/doi.org\/10.1093\/annonc\/mdx096.","DOI":"10.1093\/annonc\/mdx096"},{"key":"6858_CR25","unstructured":"National Institute for Health and Care Excellence. Myeloma: diagnosis and management [NG35]. 2016. https:\/\/www.nice.org.uk\/guidance\/ng35. Accessed Feb 2016."},{"key":"6858_CR26","doi-asserted-by":"publisher","unstructured":"Hillengass J, Moulopoulos LA, Delorme S, Koutoulidis V, Mosebach J, Hielscher T, Drake M, Rajkumar SV, Oestergaard B, Abildgaard N, Hinge M, Plesner T, Suehara Y, Matsue K, Withofs N, Caers J, Waage A, Goldschmidt H, Dimopoulos MA, Lentzsch S, Durie B, Terpos E. Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group 2017. https:\/\/doi.org\/10.1038\/bcj.2017.78.","DOI":"10.1038\/bcj.2017.78"},{"key":"6858_CR27","doi-asserted-by":"publisher","unstructured":"Baur-Melnyk A, Buhmann S, Becker C, Schoenberg SO, Lang N, Bartl R, Reiser MF. Whole-body MRI versus whole-body MDCT for staging of multiple myeloma. 2008. https:\/\/doi.org\/10.2214\/AJR.07.2635.","DOI":"10.2214\/AJR.07.2635"},{"key":"6858_CR28","doi-asserted-by":"publisher","unstructured":"Messiou C, Hillengass J, Delorme S, Lecouvet FE, Moulopoulos LA, Collins DJ, Blackledge MD, Abildgaard N, \u00d8stergaard B, Schlemmer H, Landgren O, Asmussen JT, Kaiser MF, Padhani A. Guidelines for acquisition, interpretation, and reporting of whole-body MRI in myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS). 2019. https:\/\/doi.org\/10.1148\/radiol.2019181949.","DOI":"10.1148\/radiol.2019181949"},{"key":"6858_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-014-3324-5","author":"JC Dutoit","year":"2014","unstructured":"Dutoit JC, Vanderkerken MA, Anthonissen J, Dochy F, Verstraete KL. The diagnostic value of SE MRI and DWI of the spine in patients with monoclonal gammopathy of undetermined significance, smouldering myeloma and multiple myeloma. Eur Radiol. 2014. https:\/\/doi.org\/10.1007\/s00330-014-3324-5.","journal-title":"Eur Radiol"},{"key":"6858_CR30","doi-asserted-by":"publisher","unstructured":"B\u00e4uerle T, Hillenglass J, Goldschmidt H, Delorme S, Fechtner K, Zechmann CM, Grenacher L, Moehler TM, Heiss C, Wagner-Gund B, Neben K, Kauczor H. Multiple myeloma and monoclonal gammopathy of undetermined significance: importance of whole-body versus spinal MR imaging 2009. https:\/\/doi.org\/10.1148\/radiol.2522081756.","DOI":"10.1148\/radiol.2522081756"},{"key":"6858_CR31","doi-asserted-by":"publisher","unstructured":"Dimopoulos MA, Hillengass J, Usmani S, Zamagni E, Lentzsch S, Davies FE, Raje N, Sezer O, Zweegman S, Shah J, Badros A, Shimizu K, Moreau P, Chim C, Lahuerta JJ, Hou J, Jurczyszyn A, Goldschmidt H, Sonneveld P, Palumbo A, Ludwig H, Cavo M, Barlogie B, Anderson K, Roodman GD, Rajkumar SV, Durie BGM, Terpos E. Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. 2015. https:\/\/doi.org\/10.1200\/JCO.2014.57.9961.","DOI":"10.1200\/JCO.2014.57.9961"},{"key":"6858_CR32","doi-asserted-by":"publisher","unstructured":"Terpos E, Kleber M, Engelhardt M, Zweegman S, Gay F, Kastritis E, van de Donk, Niels W C J, Bruno B, Sezer O, Broijl A, Bringhen S, Beksac M, Larocca A, Hajek R, Musto P, Johnsen HE, Morabito F, Ludwig H, Cavo M, Einsele H, Sonneveld P, Dimopoulos MA, Palumbo A. European myeloma network guidelines for the management of multiple myeloma-related complications. 2015. https:\/\/doi.org\/10.3324\/haematol.2014.117176.","DOI":"10.3324\/haematol.2014.117176"},{"key":"6858_CR33","doi-asserted-by":"publisher","unstructured":"Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, Hillengass J, Engelhardt M, Usmani SZ, Vesole DH, San-Miguel J, Kumar SK, Richardson PG, Mikhael JR, da Costa FL, Dimopoulos M, Zingaretti C, Abildgaard N, Goldschmidt H, Orlowski RZ, Chng WJ, Einsele H, Lonial S, Barlogie B, Anderson KC, Rajkumar SV, Durie BGM, Zamagni E. Role of 18F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. 2017. https:\/\/doi.org\/10.1016\/S1470-2045(17)30189-4.","DOI":"10.1016\/S1470-2045(17)30189-4"},{"key":"6858_CR34","doi-asserted-by":"publisher","unstructured":"Weng W, Dong M, Zhang J, Yang J, Xu Q, Zhu Y, Liu N. A systematic review of MRI, scintigraphy, FDG-PET and PET\/CT for Diagnosis of multiple myeloma related bone disease - which is best? 2014. https:\/\/doi.org\/10.7314\/APJCP.2014.15.22.9879.","DOI":"10.7314\/APJCP.2014.15.22.9879"},{"key":"6858_CR35","doi-asserted-by":"publisher","unstructured":"Lu Y, Chen J, Lin W, Liang J, Wang H, Tsai S, Kao C. FDG PET or PET\/CT for detecting intramedullary and extramedullary lesions in multiple myeloma: a systematic review and meta-analysis. 2012. https:\/\/doi.org\/10.1097\/RLU.0b013e31825b2071.","DOI":"10.1097\/RLU.0b013e31825b2071"},{"key":"6858_CR36","doi-asserted-by":"publisher","unstructured":"Walker RC, Brown TL, Jones-Jackson LB, De Blanche L, Bartel T. Imaging of multiple myeloma and related plasma cell dyscrasias. 2012. https:\/\/doi.org\/10.2967\/jnumed.111.098830.","DOI":"10.2967\/jnumed.111.098830"},{"key":"6858_CR37","doi-asserted-by":"publisher","DOI":"10.1007\/s00256-010-1088-9","author":"S Sager","year":"2011","unstructured":"Sager S, Erg\u00fcl N, Ciftci H, Cetin G, G\u00fcner S\u0130, Cermik TF. The value of FDG PET\/CT in the initial staging and bone marrow involvement of patients with multiple myeloma. Skeletal Radiol. 2011. https:\/\/doi.org\/10.1007\/s00256-010-1088-9.","journal-title":"Skeletal Radiol"},{"key":"6858_CR38","doi-asserted-by":"publisher","unstructured":"Mesguich C, Fardanesh R, Tanenbaum L, Chari A, Jagannath S, Kostakoglu L. State of the art imaging of multiple myeloma: Comparative review of FDG PET\/CT imaging in various clinical settings. 2014. https:\/\/doi.org\/10.1016\/j.ejrad.2014.09.012.","DOI":"10.1016\/j.ejrad.2014.09.012"},{"key":"6858_CR39","doi-asserted-by":"publisher","unstructured":"Kraeber-Bod\u00e9r\u00e9 F, Zweegman S, Perrot A, Hulin C, Caillot D, Facon T, Leleu X, Belhadj K, Itti E, Karlin L, Bailly C, Levin M, Minnema MC, Jamet B, Bodet-Milin C, De Keizer B, B\u00e9n\u00e9 MC, Avet-Loiseau H, Sonneveld P, Pei L, Rigat F, De Boer C, Vermeulen J, Kampfenkel T, Lambert J, Moreau P. Prognostic value of positron emission tomography\/computed tomography in transplanteligible newly diagnosed multiple myeloma patients from CASSIOPEIA: the CASSIOPET study. 2023. https:\/\/doi.org\/10.3324\/haematol.2021.280051.","DOI":"10.3324\/haematol.2021.280051"},{"key":"6858_CR40","doi-asserted-by":"publisher","unstructured":"Zamagni E, Patriarca F, Nanni C, Zannetti B, Englaro E, Pezzi A, Tacchetti P, Buttignol S, Perrone G, Brioli A, Pantani L, Terragna C, Carobolante F, Baccarani M, Fanin R, Fanti S, Cavo M. Prognostic relevance of 18-F FDG PET\/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. 2011. https:\/\/doi.org\/10.1182\/blood-2011-06-361386.","DOI":"10.1182\/blood-2011-06-361386"},{"issue":"25","key":"6858_CR41","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1200\/JCO.2017.72.2975","volume":"35","author":"P Moreau","year":"2017","unstructured":"Moreau P, Attal M, Caillot D, Macro M, Karlin L, Garderet L, Facon T, Benboubker L, Escoffre-Barbe M, Stoppa A, Laribi K, Hulin C, Perrot A, Marit G, Eveillard J, Caillon F, Bodet-Milin C, Pegourie B, Dorvaux V, Chaleteix C, Anderson K, Richardson P, Munshi NC, Avet-Loiseau H, Gaultier A, Nguyen J, Dupas B, Frampas E, Kraeber-Bodere F. Prospective evaluation of magnetic resonance imaging and [18F]Fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM\/DFCI 2009 trial: results of the IMAJEM study. J Clin Oncol. 2017;35(25):2911\u20138. https:\/\/doi.org\/10.1200\/JCO.2017.72.2975.","journal-title":"J Clin Oncol"},{"key":"6858_CR42","doi-asserted-by":"publisher","unstructured":"Nanni C, Versari A, Chauvie S, Bertone E, Bianchi A, Rensi M, Bell\u00f2 M, Gallamini A, Patriarca F, Gay F, Gamberi B, Ghedini P, Cavo M, Fanti S, Zamagni E. Interpretation criteria for FDG PET\/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe). Eur J Nucl Med Mol Imaging. 2018. https:\/\/doi.org\/10.1007\/s00259-017-3909-8.","DOI":"10.1007\/s00259-017-3909-8"},{"key":"6858_CR43","doi-asserted-by":"publisher","unstructured":"Rasche L, Angtuaco E, McDonald JE, Buros A, Stein C, Pawlyn C, Thanendrarajan S, Schinke C, Samant R, Yaccoby S, Walker BA, Epstein J, Zangari M, van Rhee F, Meissner T, Goldschmidt H, Hemminki K, Houlston R, Barlogie B, Davies FE, Morgan GJ, Weinhold N. Low expression of hexokinase-2 is associated with false-negative FDG\u2013positron emission tomography in multiple myeloma. 2017. https:\/\/doi.org\/10.1182\/blood-2017-03-774422.","DOI":"10.1182\/blood-2017-03-774422"},{"key":"6858_CR44","doi-asserted-by":"publisher","unstructured":"Rasche L, Chavan SS, Stephens OW, Patel PH, Tytarenko R, Ashby C, Bauer M, Stein C, Deshpande S, Wardell C, Buzder T, Molnar G, Zangari M, van Rhee F, Thanendrarajan S, Schinke C, Epstein J, Davies FE, Walker BA, Meissner T, Barlogie B, Morgan GJ, Weinhold N. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. 2017. https:\/\/doi.org\/10.1038\/s41467-017-00296-y.","DOI":"10.1038\/s41467-017-00296-y"},{"key":"6858_CR45","doi-asserted-by":"publisher","unstructured":"Rasche L, Angtuaco EJ, Alpe TL, Gershner GH, McDonald JE, Samant RS, Kumar M, Van Hemert R, Epstein J, Deshpande S, Tytarenko R, Yaccoby S, Hillengass J, Thanendrarajan S, Schinke C, van Rhee F, Zangari M, Walker BA, Barlogie B, Morgan GJ, Davies FE, Weinhold N. The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma. 2018. https:\/\/doi.org\/10.1182\/blood-2018-04-842880.","DOI":"10.1182\/blood-2018-04-842880"},{"key":"6858_CR46","doi-asserted-by":"publisher","unstructured":"Rasche L, Schinke C, Maura F, Bauer MA, Ashby C, Deshpande S, Poos AM, Zangari M, Thanendrarajan S, Davies FE, Walker BA, Barlogie B, Landgren O, Morgan GJ, van Rhee F, Weinhold N. The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states. 2022. https:\/\/doi.org\/10.1038\/s41467-022-32145-y.","DOI":"10.1038\/s41467-022-32145-y"},{"key":"6858_CR47","doi-asserted-by":"publisher","unstructured":"Alberge J, Kraeber-Bod\u00e9r\u00e9 F, Jamet B, Touzeau C, Caillon H, Wuilleme S, B\u00e9n\u00e9 M, Kampfenkel T, Sonneveld P, van Duin M, Avet-Loiseau H, Corre J, Magrangeas F, Carlier T, Bodet-Milin C, Ch\u00e9rel M, Moreau P, Minvielle S, Bailly C. Molecular signature of 18F-FDG PET biomarkers in newly diagnosed multiple myeloma patients: a genome-wide transcriptome analysis from the CASSIOPET study. 2022. https:\/\/doi.org\/10.2967\/jnumed.121.262884.","DOI":"10.2967\/jnumed.121.262884"},{"key":"6858_CR48","doi-asserted-by":"publisher","unstructured":"Zamagni E, Nanni C, Patriarca F, Englaro E, Castellucci P, Geatti O, Tosi P, Tacchetti P, Cangini D, Perrone G, Ceccolini M, Brioli A, Buttignol S, Fanin R, Salizzoni E, Baccarani M, Fanti S, Cavo M. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. 2007. https:\/\/doi.org\/10.3324\/haematol.10554.","DOI":"10.3324\/haematol.10554"},{"key":"6858_CR49","doi-asserted-by":"publisher","unstructured":"Fonti R, Pace L, Cerchione C, Catalano L, Salvatore B, De Luca S, Pane F, Salvatore M, Del Vecchio S. 18F-FDG PET\/CT, 99mTc-MIBI, and MRI in the prediction of outcome of patients with multiple myeloma: a comparative study. 2015. https:\/\/doi.org\/10.1097\/RLU.0000000000000696.","DOI":"10.1097\/RLU.0000000000000696"},{"key":"6858_CR50","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-020-05182-2","author":"O Westerland","year":"2021","unstructured":"Westerland O, Amlani A, Kelly-Morland C, Fraczek M, Bailey K, Gleeson M, El-Najjar I, Streetly M, Bassett P, Cook GJR, Goh V. Comparison of the diagnostic performance and impact on management of 18F-FDG PET\/CT and whole-body MRI in multiple myeloma. Eur J Nucl Med Mol Imaging. 2021. https:\/\/doi.org\/10.1007\/s00259-020-05182-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6858_CR51","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-021-08388-6","author":"R Burns","year":"2022","unstructured":"Burns R, Mul\u00e9 S, Blanc-Durand P, Tofighi M, Belhadj K, Zerbib P, Le Bras F, Baranes L, Haioun C, Itti E, Luciani A. Optimization of whole-body 2-[18F]FDG-PET\/MRI imaging protocol for the initial staging of patients with myeloma. Eur Radiol. 2022. https:\/\/doi.org\/10.1007\/s00330-021-08388-6.","journal-title":"Eur Radiol"},{"key":"6858_CR52","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-023-09593-1","author":"B Jamet","year":"2023","unstructured":"Jamet B, Carlier T, Bailly C, Bodet-Milin C, Monnet A, Frampas E, Touzeau C, Moreau P, Kraeber-Bodere F. Hybrid simultaneous whole-body 2-[18F]FDG-PET\/MRI imaging in newly diagnosed multiple myeloma: first diagnostic performance and clinical added value results. Eur Radiol. 2023. https:\/\/doi.org\/10.1007\/s00330-023-09593-1.","journal-title":"Eur Radiol"},{"key":"6858_CR53","doi-asserted-by":"publisher","unstructured":"Salaun P, Gastinne T, Frampas E, Bodet-Milin C, Moreau P, Bod\u00e9r\u00e9-Kraeber F. FDG-positron-emission tomography for staging and therapeutic assessment in patients with plasmacytoma. 2008. https:\/\/doi.org\/10.3324\/haematol.12654.","DOI":"10.3324\/haematol.12654"},{"key":"6858_CR54","doi-asserted-by":"publisher","unstructured":"Fouquet G, Guidez S, Berthon C, Terriou L, Coiteux V, Macro Margaret, Decaux O, Facon T, Huglo D, Leleu X, Herbaux C, Van De Wyngaert Z, Bonnet Sarah, Beauvais D, Demarquette H, Adib S, Hivert B, Wemeau M. Impact of initial FDG-PET\/CT and serum-free light chain on transformation of conventionally defined solitary plasmacytoma to multiple myeloma. 2014. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-2910.","DOI":"10.1158\/1078-0432.CCR-13-2910"},{"key":"6858_CR55","doi-asserted-by":"publisher","unstructured":"Siontis B, Kumar S, Dispenzieri A, Drake MT, Lacy MQ, Buadi F, Dingli D, Kapoor P, Gonsalves W, Gertz MA, Rajkumar SV. Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy. 2015.https:\/\/doi.org\/10.1038\/bcj.2015.87.","DOI":"10.1038\/bcj.2015.87"},{"key":"6858_CR56","doi-asserted-by":"publisher","unstructured":"Zamagni E, Nanni C, Gay F, Pezzi A, Patriarca F, Bell\u00f2 M, Rambaldi I, Tacchetti P, Hillengass J, Gamberi B, Pantani L, Magarotto V, Versari A, Offidani M, Zannetti B, Carobolante F, Balma M, Musto P, Rensi M, Mancuso K, Dimitrakopoulou-Strauss A, Chauvi\u00e8 S, Rocchi S, Fard N, Marzocchi G, Storto G, Ghedini P, Palumbo A, Fanti S, Cavo M. 18F-FDG PET\/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease. 2016. https:\/\/doi.org\/10.1038\/leu.2015.291.","DOI":"10.1038\/leu.2015.291"},{"key":"6858_CR57","doi-asserted-by":"publisher","unstructured":"Kyle RA, Larson DR, Therneau TM, Dispenzieri A, Kumar S, Cerhan JR, Rajkumar SV. Long-term follow-up of monoclonal gammopathy of undetermined significance. 2018. https:\/\/doi.org\/10.1056\/NEJMoa1709974.","DOI":"10.1056\/NEJMoa1709974"},{"key":"6858_CR58","doi-asserted-by":"publisher","unstructured":"Rudolphi\u2010Solero T, Trivi\u00f1o\u2010Ib\u00e1\u00f1ez EM, Gonz\u00e1lez\u2010Jim\u00e9nez AD, Ramos\u2010Font C, R\u00edos\u2010Tamayo R, Rebollo\u2010Aguirre AC, S\u00e1nchez\u2010S\u00e1nchez R. Diagnostic relevance of 2\u2010[18F]\u2010FDG PET\/CT in patients recently diagnosed with monoclonal gammopathy of undetermined significance. 2023. https:\/\/doi.org\/10.1002\/hon.3085.","DOI":"10.1002\/hon.3085"},{"key":"6858_CR59","doi-asserted-by":"publisher","unstructured":"Bartel TB, Haessler J, Brown TLY, Shaughnessy JD, van Rhee F, Anaissie E, Alpe T, Angtuaco E, Walker R, Epstein J, Crowley J, Barlogie B. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. 2009. https:\/\/doi.org\/10.1182\/blood-2009-03-213280.","DOI":"10.1182\/blood-2009-03-213280"},{"key":"6858_CR60","doi-asserted-by":"publisher","unstructured":"Michaud-Robert A, Zamagni E, Carlier T, Bailly C, Jamet B, Touzeau C, Moreau P, Kraeber-Bodere F, Nanni C, Bodet-Milin C. Glucose metabolism quantified by SUVmax on baseline FDG-PET\/CT predicts survival in newly diagnosed multiple myeloma patients: combined harmonized analysis of two prospective phase iii trials. 2020. https:\/\/doi.org\/10.3390\/cancers12092532.","DOI":"10.3390\/cancers12092532"},{"issue":"6","key":"6858_CR61","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s00259-019-04312-9","volume":"46","author":"Y Abe","year":"2019","unstructured":"Abe Y, Ikeda S, Kitadate A, Narita K, Kobayashi H, Miura D, Takeuchi M, O\u2019uchi E, O\u2019uchi T, Matsue K. Low hexokinase-2 expression-associated false-negative 18 F-FDG PET\/CT as a potential prognostic predictor in patients with multiple myeloma. Eur J Nucl Med Mol Imaging. 2019;46(6):1345\u201350. https:\/\/doi.org\/10.1007\/s00259-019-04312-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6858_CR62","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-017-3810-5","author":"D Albano","year":"2018","unstructured":"Albano D, Bosio G, Treglia G, Giubbini R, Bertagna F. 18F\u2013FDG PET\/CT in solitary plasmacytoma: metabolic behavior and progression to multiple myeloma. Eur J Nucl Med Mol Imaging. 2018. https:\/\/doi.org\/10.1007\/s00259-017-3810-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6858_CR63","doi-asserted-by":"publisher","unstructured":"Rama S, Suh CH, Kim KW, Durieux JC, Ramaiya NH, Tirumani SH. Comparative performance of whole-body MRI and FDG PET\/CT in evaluation of multiple myeloma treatment response: systematic review and meta-analysis. 2022. https:\/\/doi.org\/10.2214\/AJR.21.26381.","DOI":"10.2214\/AJR.21.26381"},{"key":"6858_CR64","doi-asserted-by":"publisher","unstructured":"Rasche L, Alapat D, Kumar M, Gershner G, McDonald J, Wardell CP, Samant R, Van Hemert R, Epstein J, Williams AF, Thanendrarajan S, Schinke C, Bauer M, Ashby C, Tytarenko RG, van Rhee F, Walker BA, Zangari M, Barlogie B, Davies FE, Morgan GJ, Weinhold N. Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma. 2019. https:\/\/doi.org\/10.1038\/s41375-018-0329-0.","DOI":"10.1038\/s41375-018-0329-0"},{"key":"6858_CR65","doi-asserted-by":"publisher","unstructured":"Nanni C, Kobe C, Bae\u00dfler B, Baues C, Boellaard R, Borchmann P, Buck A, Buvat I, Chapuy B, Cheson BD, Chrzan R, Cottereau A, D\u00fchrsen U, Eikenes L, Hutchings M, Jurczak W, Kraeber-Bod\u00e9r\u00e9 F, Lopci E, Luminari S, MacLennan S, Mikhaeel NG, Nijland M, Rodr\u00edguez-Otero P, Treglia G, Withofs N, Zamagni E, Zinzani PL, Zijlstra JM, Herrmann K, Kunikowska J. European Association of Nuclear Medicine (EANM) focus 4 consensus recommendations: molecular imaging and therapy in haematological tumours. 2023. https:\/\/doi.org\/10.1016\/S2352-3026(23)00030-3.","DOI":"10.1016\/S2352-3026(23)00030-3"},{"key":"6858_CR66","doi-asserted-by":"publisher","unstructured":"Zamagni E, Nanni C, Mancuso K, Tacchetti P, Pezzi A, Pantani L, Zannetti B, Rambaldi I, Brioli A, Rocchi S, Terragna C, Martello M, Marzocchi G, Borsi E, Rizzello I, Fanti S, Cavo M. PET\/CT improves the definition of complete response and allows to detect otherwise unidentifiable skeletal progression in multiple myeloma. 2015. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0396.","DOI":"10.1158\/1078-0432.CCR-15-0396"},{"key":"6858_CR67","doi-asserted-by":"publisher","unstructured":"Zamagni E, Nanni C, Dozza L, Carlier T, Bailly C, Tacchetti P, Versari A, Chauvie S, Gallamini A, Gamberi B, Caillot D, Patriarca F, Macro M, Boccadoro M, Garderet L, Barbato S, Fanti S, Perrot A, Gay F, Sonneveld P, Karlin L, Cavo M, Bodet-Milin C, Moreau P, Kraeber-Bod\u00e9r\u00e9 F. Standardization of 18 F-FDG\u2013PET\/CT according to deauville criteria for metabolic complete response definition in newly diagnosed multiple myeloma. 2021. https:\/\/doi.org\/10.1200\/jco.20.00386.","DOI":"10.1200\/jco.20.00386"},{"key":"6858_CR68","doi-asserted-by":"publisher","unstructured":"Davies FE, Rosenthal A, Rasche L, Petty NM, McDonald JE, Ntambi JA, Steward DM, Panozzo SB, van Rhee F, Zangari M, Schinke CD, Thanendrarajan S, Walker B, Weinhold N, Barlogie B, Hoering A, Morgan GJ. Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma. 2018. https:\/\/doi.org\/10.3324\/haematol.2017.177139.","DOI":"10.3324\/haematol.2017.177139"},{"key":"6858_CR69","doi-asserted-by":"publisher","unstructured":"Zamagni E, Oliva S, Gay F, Capra A, Rota-Scalabrini D, D'Agostino M, Belotti A, Galli M, Racca M, Zambello R, Gamberi B, Albano D, Bertamini L, Versari A, Grasso M, Sgherza N, Priola C, Fioritoni F, Patriarca F, De Cicco G, Villanova T, Pascarella A, Zucchetta P, Tacchetti P, Fanti S, Mancuso K, Barbato S, Boccadoro M, Musto P, Cavo M, Nanni C. Impact of minimal residual disease standardised assessment by FDG-PET\/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial. 2023. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102017.","DOI":"10.1016\/j.eclinm.2023.102017"},{"key":"6858_CR70","doi-asserted-by":"publisher","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Blad\u00e9 J, Mateos M, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau J, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, Miguel JS, Avet-Loiseau H. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. 2016. https:\/\/doi.org\/10.1016\/S1470-2045(16)30206-6.","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"6858_CR71","doi-asserted-by":"publisher","unstructured":"Munshi NC, Avet-Loiseau H, Anderson KC, Neri P, Paiva B, Samur M, Dimopoulos M, Kulakova M, Lam A, Hashim M, He J, Heeg B, Ukropec J, Vermeulen J, Cote S, Bahlis N. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. 2020. https:\/\/doi.org\/10.1182\/bloodadvances.2020002827.","DOI":"10.1182\/bloodadvances.2020002827"},{"key":"6858_CR72","doi-asserted-by":"publisher","unstructured":"Fonseca R, Arribas M, Wiedmeier-Nutor JE, Kusne YN, Gonz\u00e1lez V\u00e9lez M, Kosiorek HE, Butterfield RDJ, Kirsch IR, Mikhael JR, Stewart AK, Reeder C, Larsen J, Bergsagel PL, Fonseca R. Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients. 2023. https:\/\/doi.org\/10.1038\/s41408-023-00794-x.","DOI":"10.1038\/s41408-023-00794-x"},{"key":"6858_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.29","author":"KD Short","year":"2011","unstructured":"Short KD, Rajkumar SV, Larson D, Buadi F, Hayman S, Dispenzieri A, Gertz M, Kumar S, Mikhael J, Roy V, Kyle RA, Lacy MQ. Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia. 2011. https:\/\/doi.org\/10.1038\/leu.2011.29.","journal-title":"Leukemia"},{"key":"6858_CR74","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.065698","author":"SZ Usmani","year":"2012","unstructured":"Usmani SZ, Heuck C, Mitchell A, Szymonifka J, Nair B, Hoering A, Alsayed Y, Waheed S, Haider S, Restrepo A, Van Rhee F, Crowley J, Barlogie B. Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica. 2012. https:\/\/doi.org\/10.3324\/haematol.2012.065698.","journal-title":"Haematologica"},{"key":"6858_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.04.002","author":"S Sevcikova","year":"2019","unstructured":"Sevcikova S, Minarik J, Stork M, Jelinek T, Pour L, Hajek R. Extramedullary disease in multiple myeloma - controversies and future directions. Blood Rev. 2019. https:\/\/doi.org\/10.1016\/j.blre.2019.04.002.","journal-title":"Blood Rev"},{"key":"6858_CR76","doi-asserted-by":"publisher","unstructured":"Mesguich C, Hulin C, Latrabe V, Lascaux A, Bordenave L, Hindi\u00e9 E. 18F-FDG PET\/CT and MRI in the management of multiple myeloma: a comparative review. 2022. https:\/\/doi.org\/10.3389\/fnume.2021.808627.","DOI":"10.3389\/fnume.2021.808627"},{"key":"6858_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01012-4","author":"LJ Costa","year":"2021","unstructured":"Costa LJ, Derman BA, Bal S, Sidana S, Chhabra S, Silbermann R, Ye JC, Cook G, Cornell RF, Holstein SA, Shi Q, Omel J, Callander NS, Chng WJ, Hungria V, Maiolino A, Stadtmauer E, Giralt S, Pasquini M, Jakubowiak AJ, Morgan GJ, Krishnan A, Jackson GH, Mohty M, Mateos MV, Dimopoulos MA, Facon T, Spencer A, Miguel JS, Hari P, Usmani SZ, Manier S, McCarthy P, Kumar S, Gay F, Paiva B. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia. 2021. https:\/\/doi.org\/10.1038\/s41375-020-01012-4.","journal-title":"Leukemia"},{"key":"6858_CR78","doi-asserted-by":"publisher","unstructured":"Moreau P, Zweegman S, Perrot A, Hulin C, Caillot D, Facon T, Leleu X, Belhadj K, Karlin L, Benboubker L, Levin M, Minnema MC, Jamet B, Bodet-Milin C, Sonneveld P, Lambert J, Pei L, de Boer C, Vermeulen J, Kampfenkel T, Kraeber-Bodere F. Evaluation of the prognostic value of Positron Emission Tomography-Computed Tomography (PET-CT) at diagnosis and follow-up in Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) patients treated in the phase 3 cassiopeia study: results of the cassiopet companion study. 2019. https:\/\/doi.org\/10.1182\/blood-2019-123143.","DOI":"10.1182\/blood-2019-123143"},{"key":"6858_CR79","doi-asserted-by":"publisher","unstructured":"Nanni C, Zamagni E, Versari A, Chauvie S, Bianchi A, Rensi M, Bell\u00f2 M, Rambaldi I, Gallamini A, Patriarca F, Gay F, Gamberi B, Cavo M, Fanti S. Image interpretation criteria for FDG PET\/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe). Eur J Nucl Med Mol Imaging. 2016. https:\/\/doi.org\/10.1007\/s00259-015-3200-9.","DOI":"10.1007\/s00259-015-3200-9"},{"key":"6858_CR80","doi-asserted-by":"publisher","unstructured":"Kircher S, Stolzenburg A, Kort\u00fcm KM, Kircher M, Da Via M, Samnick S, Buck AK, Einsele H, Rosenwald A, Lapa C. Hexokinase-2 expression in 11 C-methionine\u2013positive, 18 F-FDG\u2013negative multiple myeloma. 2019. https:\/\/doi.org\/10.2967\/jnumed.118.217539.","DOI":"10.2967\/jnumed.118.217539"},{"key":"6858_CR81","doi-asserted-by":"publisher","unstructured":"Jamet B, Bodet-Milin C, Moreau P, Kraeber-Bod\u00e9r\u00e9 F, Touzeau C. 2-[18F]FDG PET\/CT flare-up phenomena following T-cell engager bispecific antibody in multiple myeloma. 2023. https:\/\/doi.org\/10.1097\/RLU.0000000000004588.","DOI":"10.1097\/RLU.0000000000004588"},{"key":"6858_CR82","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.2290","author":"C Lapa","year":"2014","unstructured":"Lapa C, Luckerath K, Malzahn U, Samnick S, Einsele H, Buck AK, Herrmann K, Knop S. 18 FDG-PET\/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantation. Oncotarget. 2014. https:\/\/doi.org\/10.18632\/oncotarget.2290.","journal-title":"Oncotarget"},{"key":"6858_CR83","doi-asserted-by":"publisher","unstructured":"Paiva B, Puig N, Cedena M, Rosi\u00f1ol L, Cord\u00f3n L, Vidriales M, Burgos L, Flores-Montero J, Sanoja-Flores L, Lopez-Anglada L, Maldonado R, de la Cruz J, Gutierrez NC, Calasanz M, Martin-Ramos M, Garcia-Sanz R, Martinez-Lopez J, Oriol A, Blanchard M, Rios R, Martin J, Martinez-Martinez R, Sureda A, Hernandez M, de la Rubia J, Krsnik I, Moraleda J, Palomera L, Bargay J, Van Dongen JJM, Orfao A, Mateos M, Blade J, San-Miguel JF, Lahuerta J. Measurable residual disease by next-generation flow cytometry in multiple myeloma 2020. https:\/\/doi.org\/10.1200\/JCO.19.01231.","DOI":"10.1200\/JCO.19.01231"},{"key":"6858_CR84","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13174323","author":"G Fouquet","year":"2021","unstructured":"Fouquet G, Wartski M, Dechmi A, Willems L, Deau-Fischer B, Franchi P, Descroocq J, Deschamps P, Blanc-Autran E, Clerc J, Bouscary D, Barreau S, Chapuis N, Vignon M, Cottereau A. Prognostic value of FDG-PET\/CT parameters in patients with relapse\/refractory multiple myeloma before anti-CD38 based therapy. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13174323.","journal-title":"Cancers (Basel)"},{"key":"6858_CR85","doi-asserted-by":"publisher","unstructured":"Zukovs R, Antke C, Mamlins E, Sawicki LM, Mohring A, Lopez Y Niedenhoff D, Boquoi A, Kondakci M, Antoch G, M\u00fcller H, Fenk R, Haas R. 18F-FDG-PET\/CT in relapsed multiple myeloma: are prognostic thresholds different from first-line therapy? 2022. https:\/\/doi.org\/10.1186\/s12880-022-00788-4.","DOI":"10.1186\/s12880-022-00788-4"},{"key":"6858_CR86","doi-asserted-by":"publisher","unstructured":"Jamet B, Bailly C, Carlier T, Planche L, Touzeau C, Kraeber-Bod\u00e9r\u00e9 F, Moreau P, Bodet-Milin C. Added prognostic value of FDG-PET\/CT in relapsing multiple myeloma patients. 2019. https:\/\/doi.org\/10.1080\/10428194.2018.1459602.","DOI":"10.1080\/10428194.2018.1459602"},{"key":"6858_CR87","doi-asserted-by":"publisher","unstructured":"Dankerl A, Liebisch P, Glatting G, Friesen C, Blumstein NM, Kocot D, Wendl C, Bunjes D, Reske SN. Multiple myeloma: molecular imaging with C-methionine PET\/CT\u2014initial experience. 2007. https:\/\/doi.org\/10.1148\/radiol.2422051980.","DOI":"10.1148\/radiol.2422051980"},{"key":"6858_CR88","doi-asserted-by":"publisher","unstructured":"Lapa C, Garcia-Velloso MJ, L\u00fcckerath K, Samnick S, Schreder M, Otero PR, Schmid J, Herrmann K, Knop S, Buck AK, Einsele H, San-Miguel J, Kort\u00fcm KM. 11C-Methionine-PET in multiple myeloma: a combined study from two different institutions. 2017. https:\/\/doi.org\/10.7150\/thno.20491.","DOI":"10.7150\/thno.20491"},{"key":"6858_CR89","doi-asserted-by":"publisher","unstructured":"Filippi L, Frantellizzi V, Bartoletti P, Vincentis GD, Schillaci O, Evangelista L. Head-to-head comparison between FDG and 11C-methionine in multiple myeloma: a systematic review. 2023. https:\/\/doi.org\/10.3390\/diagnostics13122009.","DOI":"10.3390\/diagnostics13122009"},{"key":"6858_CR90","doi-asserted-by":"publisher","unstructured":"Wang Y, Yee A, Bernstein Z, O'Donnell E, Raje N, Mahmood U. Carbon-11-labeled methionine PET\/CT in patients with FDG-occult multiple myeloma: a prospective pilot study. 2023. https:\/\/doi.org\/10.2214\/AJR.22.28560.","DOI":"10.2214\/AJR.22.28560"},{"key":"6858_CR91","doi-asserted-by":"publisher","unstructured":"Czy\u017c J, Ma\u0142kowski B, Jurczyszyn A, Grz\u0105\u015bko N, \u0141opatto R, Olejniczak M, Czy\u017c A, Jachalska A. 18F-fluoro-ethyl-tyrosine (18F-FET) PET\/CT as a potential new diagnostic tool in multiple myeloma: a preliminary study. 2019. https:\/\/doi.org\/10.5114\/wo.2019.83342.","DOI":"10.5114\/wo.2019.83342"},{"key":"6858_CR92","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-022-00876-0","author":"V Morath","year":"2022","unstructured":"Morath V, Heider M, Mittelhauser M, Rolbieski H, Stroh J, Calais J, Eiber M, Bassermann F, Weber WA. Initial evaluation of [(18)F]-FACBC for PET imaging of multiple myeloma. EJNMMI Res. 2022. https:\/\/doi.org\/10.1186\/s13550-022-00876-0.","journal-title":"EJNMMI Res"},{"key":"6858_CR93","doi-asserted-by":"publisher","unstructured":"B\u00f6gelein A, Stolzenburg A, Eiring P, L\u00fcckerath K, Munawar U, Werner R, Schirbel A, Samnick S, Kort\u00fcm KM, Sauer M, Lapa C, Buck AK. CXCR4 expression of multiple myeloma as a dynamic process: influence of therapeutic agents. 2022. https:\/\/doi.org\/10.1080\/10428194.2022.2074986.","DOI":"10.1080\/10428194.2022.2074986"},{"key":"6858_CR94","doi-asserted-by":"publisher","DOI":"10.1007\/s40336-023-00573-5","author":"M Wang","year":"2023","unstructured":"Wang M, Zhang J, Liu L, Wang J, Zhang C. The role of 68Ga-Pentixafor PET in multiple myeloma. Clin Transl Imaging. 2023. https:\/\/doi.org\/10.1007\/s40336-023-00573-5.","journal-title":"Clin Transl Imaging"},{"key":"6858_CR95","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201404698","author":"K Philipp-Abbrederis","year":"2015","unstructured":"Philipp-Abbrederis K, Herrmann K, Knop S, Schottelius M, Eiber M, Luckerath K, Pietschmann E, Habringer S, Gerngross C, Franke K, Rudelius M, Schirbel A, Lapa C, Schwamborn K, Steidle S, Hartmann E, Rosenwald A, Kropf S, Beer AJ, Peschel C, Einsele H, Buck AK, Schwaiger M, Gotze K, Wester H, Keller U. In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma. EMBO Mol Med. 2015. https:\/\/doi.org\/10.15252\/emmm.201404698.","journal-title":"EMBO Mol Med"},{"key":"6858_CR96","doi-asserted-by":"publisher","unstructured":"Lapa C, Schreder M, Schirbel A, Samnick S, Kort\u00fcm KM, Herrmann K, Kropf S, Einsele H, Buck AK, Wester H, Knop S, L\u00fcckerath K. [ 68 Ga]Pentixafor-PET\/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - comparison to [ 18 F]FDG and laboratory values. 2017. https:\/\/doi.org\/10.7150\/thno.16576.","DOI":"10.7150\/thno.16576"},{"key":"6858_CR97","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-019-04605-z","author":"Q Pan","year":"2020","unstructured":"Pan Q, Cao X, Luo Y, Li J, Feng J, Li F. Chemokine receptor-4 targeted PET\/CT with 68Ga-Pentixafor in assessment of newly diagnosed multiple myeloma: comparison to 18F-FDG PET\/CT. Eur J Nucl Med Mol Imaging. 2020. https:\/\/doi.org\/10.1007\/s00259-019-04605-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"6858_CR98","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.2967\/jnumed.121.263693","volume":"63","author":"AK Buck","year":"2022","unstructured":"Buck AK, Haug A, Dreher N, Lambertini A, Higuchi T, Lapa C, Weich A, Pomper MG, Wester HJ, Zehndner A, Schirbel A, Samnick S, Hacker M, Pichler V, Hahner S, Fassnacht M, Einsele H, Serfling SE, Werner RA. Imaging of C-X-C motif chemokine receptor 4 expression in 690 patients with solid or hematologic neoplasms using 68Ga-Pentixafor PET. J Nucl Med. 2022;63(11):1687\u201392. https:\/\/doi.org\/10.2967\/jnumed.121.263693.","journal-title":"J Nucl Med"},{"key":"6858_CR99","doi-asserted-by":"publisher","unstructured":"Herrmann K, Schottelius M, Lapa C, Osl T, Poschenrieder A, H\u00e4nscheid H, L\u00fcckerath K, Schreder M, Bluemel C, Knott M, Keller U, Schirbel A, Samnick S, Lassmann M, Kropf S, Buck AK, Einsele H, Wester H, Knop S. First-in-human experience of CXCR4-directed endoradiotherapy with 177Lu- and 90Y-labeled pentixather in advanced-stage multiple myeloma with extensive intra- and extramedullary disease. 2016. https:\/\/doi.org\/10.2967\/jnumed.115.167361.","DOI":"10.2967\/jnumed.115.167361"},{"key":"6858_CR100","doi-asserted-by":"publisher","unstructured":"Chen M, Zhu W, Du J, Yang C, Han B, Zhou D, Huo L, Zhuang J. 11C-acetate positron emission tomography is more precise than 18F-fluorodeoxyglucose positron emission tomography in evaluating tumor burden and predicting disease risk of multiple myeloma. 2021. https:\/\/doi.org\/10.1038\/s41598-021-01740-2.","DOI":"10.1038\/s41598-021-01740-2"},{"key":"6858_CR101","doi-asserted-by":"publisher","unstructured":"Ho C, Chen S, Leung YL, Cheng T, Wong K, Cheung SK, Liang R, Chim CS. 11C-acetate PET\/CT for metabolic characterization of multiple myeloma: a comparative study with 18F-FDG PET\/CT. 2014. https:\/\/doi.org\/10.2967\/jnumed.113.131169.","DOI":"10.2967\/jnumed.113.131169"},{"issue":"3","key":"6858_CR102","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1148\/radiol.2020192621","volume":"295","author":"GA Ulaner","year":"2020","unstructured":"Ulaner GA, Sobol NB, O\u2019Donoghue JA, Kirov AS, Riedl CC, Min R, Smith E, Carter LM, Lyashchenko SK, Lewis JS, Landgren CO. CD38-targeted immuno-PET of multiple myeloma: from xenograft models to first-in-human imaging. Radiology. 2020;295(3):606\u201315. https:\/\/doi.org\/10.1148\/radiol.2020192621.","journal-title":"Radiology"},{"key":"6858_CR103","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-020-05049-6","author":"B Jamet","year":"2021","unstructured":"Jamet B, Morvan L, Nanni C, Michaud A, Bailly C, Chauvie S, Moreau P, Touzeau C, Zamagni E, Bodet-Milin C, Kraeber-Bod\u00e9r\u00e9 F, Mateus D, Carlier T. Random survival forest to predict transplant-eligible newly diagnosed multiple myeloma outcome including FDG-PET radiomics: a combined analysis of two independent prospective European trials. Eur J Nucl Med Mol Imaging. 2021. https:\/\/doi.org\/10.1007\/s00259-020-05049-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6858_CR104","doi-asserted-by":"publisher","unstructured":"McDonald JE, Kessler MM, Gardner MW, Buros AF, Ntambi JA, Waheed S, van Rhee F, Zangari M, Heuck CJ, Petty N, Schinke C, Thanendrarajan S, Mitchell A, Hoering A, Barlogie B, Morgan GJ, Davies FE. Assessment of total lesion glycolysis by 18F FDG PET\/CT significantly improves prognostic value of GEP and ISS in myeloma. 2017. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0235.","DOI":"10.1158\/1078-0432.CCR-16-0235"},{"key":"6858_CR105","doi-asserted-by":"publisher","unstructured":"Terao T, Machida Y, Tsushima T, Miura D, Narita K, Kitadate A, Takeuchi M, Matsue K. Pre\u2010treatment metabolic tumour volume and total lesion glycolysis are superior to conventional positron\u2010emission tomography\/computed tomography variables for outcome prediction in patients with newly diagnosed multiple myeloma in clinical practice. 2020. https:\/\/doi.org\/10.1111\/bjh.16633.","DOI":"10.1111\/bjh.16633"},{"key":"6858_CR106","doi-asserted-by":"publisher","unstructured":"Fonti R, Larobina M, Del Vecchio S, De Luca S, Fabbricini R, Catalano L, Pane F, Salvatore M, Pace L. Metabolic tumor volume assessed by 18F-FDG PET\/CT for the prediction of outcome in patients with multiple myeloma. 2012. https:\/\/doi.org\/10.2967\/jnumed.112.106500.","DOI":"10.2967\/jnumed.112.106500"},{"key":"6858_CR107","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-019-03852-2","author":"R Fonti","year":"2020","unstructured":"Fonti R, Pellegrino S, Catalano L, Pane F, Del Vecchio S, Pace L. Visual and volumetric parameters by 18F-FDG-PET\/CT: a head to head comparison for the prediction of outcome in patients with multiple myeloma. Ann Hematol. 2020. https:\/\/doi.org\/10.1007\/s00277-019-03852-2.","journal-title":"Ann Hematol"},{"key":"6858_CR108","doi-asserted-by":"publisher","unstructured":"Terao T, Machida Y, Hirata K, Kuzume A, Tabata R, Tsushima T, Miura D, Narita K, Takeuchi M, Tateishi U, Matsue K. Prognostic impact of metabolic heterogeneity in patients with newly diagnosed multiple myeloma using 18F-FDG PET\/CT. 2021. https:\/\/doi.org\/10.1097\/RLU.0000000000003773.","DOI":"10.1097\/RLU.0000000000003773"},{"key":"6858_CR109","doi-asserted-by":"publisher","DOI":"10.1007\/s11548-019-02015-y","author":"L Morvan","year":"2020","unstructured":"Morvan L, Carlier T, Jamet B, Bailly C, Bodet-Milin C, Moreau P, Kraeber-Bod\u00e9r\u00e9 F, Mateus D. Leveraging RSF and PET images for prognosis of multiple myeloma at diagnosis. Int J CARS. 2020. https:\/\/doi.org\/10.1007\/s11548-019-02015-y.","journal-title":"Int J CARS"},{"key":"6858_CR110","doi-asserted-by":"publisher","unstructured":"Tagliafico AS, Cea M, Rossi F, Valdora F, Bignotti B, Succio G, Gualco S, Conte A, Dominietto A. Differentiating diffuse from focal pattern on Computed Tomography in multiple myeloma: added value of a radiomics approach. 2019. https:\/\/doi.org\/10.1016\/j.ejrad.2019.108739.","DOI":"10.1016\/j.ejrad.2019.108739"},{"key":"6858_CR111","doi-asserted-by":"publisher","unstructured":"Park H, Lee S, Lee J, Pak J, Lee K, Lee S, Jung J. Detecting multiple myeloma infiltration of the bone marrow on ct scans in patients with osteopenia: feasibility of radiomics analysis. 2022. https:\/\/doi.org\/10.3390\/diagnostics12040923.","DOI":"10.3390\/diagnostics12040923"},{"key":"6858_CR112","doi-asserted-by":"publisher","unstructured":"Jin Z, Wang Y, Wang Y, Mao Y, Zhang F, Yu J. Application of 18F-FDG PET-CT images based radiomics in identifying vertebral multiple myeloma and bone metastases. 2022. https:\/\/doi.org\/10.3389\/fmed.2022.874847.","DOI":"10.3389\/fmed.2022.874847"},{"key":"6858_CR113","doi-asserted-by":"publisher","unstructured":"Liu J, Zeng P, Guo W, Wang C, Geng Y, Lang N, Yuan H. Prediction of high\u2010risk cytogenetic status in multiple myeloma based on magnetic resonance imaging: utility of radiomics and comparison of machine learning methods. 2021. https:\/\/doi.org\/10.1002\/jmri.27637.","DOI":"10.1002\/jmri.27637"},{"key":"6858_CR114","doi-asserted-by":"publisher","DOI":"10.1007\/s13246-023-01265-0","author":"E Milara","year":"2023","unstructured":"Milara E, Alonso R, Masseing L, Seiffert AP, G\u00f3mez-Grande A, G\u00f3mez EJ, Mart\u00ednez-L\u00f3pez J, S\u00e1nchez-Gonz\u00e1lez P. Radiomics analysis of bone marrow biopsy locations in [18F]FDG PET\/CT images for measurable residual disease assessment in multiple myeloma. Phys Eng Sci Med. 2023. https:\/\/doi.org\/10.1007\/s13246-023-01265-0.","journal-title":"Phys Eng Sci Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06858-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-024-06858-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06858-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T09:06:26Z","timestamp":1732611986000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-024-06858-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,29]]},"references-count":114,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["6858"],"URL":"https:\/\/doi.org\/10.1007\/s00259-024-06858-9","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,29]]},"assertion":[{"value":"24 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate"}},{"value":"CN has received consultant honoraria from Keosys and funding from Radius, Immedica, Thema Sinergie. CMD has received consultant honoraria from Sirtex, Advanced Accelerator Applications, Novartis, Ipsen, Terumo, PSI CRO and Immedica Pharma; his institution has received travel support from GE Healthcare, Sirtex. CL has received research funding from RayzeBio and consultant honoraria from Blue Earth Diagnostics Ltd. (BED, Oxford, UK) and Novartis. NW has received consultant honoraria from Novartis and SCK CEN. EZ has served consulting\/advisory role and received honoraria from Janssen, Bristol-Myers Squibb, Sanofi, Amgen, GlaxoSmithKline, Pfizer, Oncopeptides, Menarini Stemline. MD has received speaker honoraria from BMS, GSK, Janssen, Sanofi, Stemline. FKB has received consultant honoraria from Novartis AAA, Telix pharmaceuticals and Immedica and research funding from Siemens.SB, MS, BJ, DI have no relevant financial or non-financial interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This guideline summarizes the views of the EANM Oncology and Theranostics Committee. It reflects recommendations for which the EANM cannot be held responsible. The recommendations should be taken into context of good practice of nuclear medicine and do not substitute for national and international legal or regulatory provisions.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Liability statement"}}]}}